Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

157.96 

0.79 0.5%

as of Aug 19 '19

52 Week Range:

118.10 165.14


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 7.80
9.70
11.12
11.60
12.52
13.87
16.82
15.71
18.19
20.85
24.73
growth rate 24.4% 14.6% 4.3% 7.9% 10.8% 21.3% -6.6% 15.8% 14.6% 18.6%
Earnings BIT 98.28
104.67
92.72
29.00
69.20
122.20
211.15
281.54
319.85
343.59
385.85
growth rate 6.5% -11.4% -68.7% 138.6% 76.6% 72.8% 33.3% 13.6% 7.4% 12.3%
Avg.PE 15.17
13.81
15.24
45.66
30.30
24.45
24.64
18.12
17.95
22.13
23.36
growth rate -9.0% 10.4% 199.6% -33.6% -19.3% 0.8% -26.5% -0.9% 23.3% 5.6%
ROA 10.01
10.62
9.37
2.31
4.95
7.78
11.61
14.75
14.79
14.17
14.34
growth rate 6.1% -11.8% -75.4% 114.3% 57.2% 49.2% 27.1% 0.3% -4.2% 1.2%
ROE 18.50
18.34
14.02
3.39
7.72
12.35
18.54
27.96
30.70
26.35
25.35
growth rate -0.9% -23.6% -75.8% 127.7% 60.0% 50.1% 50.8% 9.8% -14.2% -3.8%
ROIC 15.13
18.82
13.92
3.44
7.81
12.38
18.50
20.04
22.62
20.49
20.37
growth rate 24.4% -26.0% -75.3% 127.0% 58.5% 49.4% 8.3% 12.9% -9.4% -0.6%
Cur. Ratio 1.59
1.79
2.32
1.83
1.61
1.70
1.52
1.51
1.94
1.95
2.18
growth rate 12.6% 29.6% -21.1% -12.0% 5.6% -10.6% -0.7% 28.5% 0.5% 11.8%
Quick Ratio 1.05
1.38
1.81
1.30
1.50
1.60
1.42
1.45
1.87
1.88
2.12
growth rate 31.4% 31.2% -28.2% 15.4% 6.7% -11.3% 2.1% 29.0% 0.5% 12.8%
Leverage 1.90
1.59
1.42
1.52
1.59
1.58
1.60
2.25
1.93
1.80
1.74
growth rate -16.3% -10.7% 7.0% 4.6% -0.6% 1.3% 40.6% -14.2% -6.7% -3.3%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 210.50
191.90
164.90
363.97
285.40
342.60
550.33
636.71
662.20
706.19
837.62
growth rate -8.8% -14.1% 120.7% -21.6% 20.0% 60.6% 15.7% 4.0% 6.6% 18.6%
Acct.Payable 160.10
8.10
4.60
2.79
7.02
8.70
60.38
46.53
growth rate -94.9% -43.2% -39.3% 151.4% 23.9% 594.3% -22.9%
Cur.Assets 500.30
535.40
579.70
559.57
663.70
853.40
819.51
862.74
957.96
1,101.02
1,330.18
growth rate 7.0% 8.3% -3.5% 18.6% 28.6% -4.0% 5.3% 11.0% 14.9% 20.8%
Total Assets 867.30
908.40
949.50
1,027.52
1,202.10
1,442.50
1,528.85
1,717.21
1,825.84
2,146.62
2,354.26
growth rate 4.7% 4.5% 8.2% 17.0% 20.0% 6.0% 12.3% 6.3% 17.6% 9.7%
Cash 58.40
144.80
255.70
119.24
114.00
182.50
118.90
103.91
192.54
282.86
395.85
growth rate 148.0% 76.6% -53.4% -4.4% 60.1% -34.9% -12.6% 85.3% 46.9% 40.0%
Inventory 0.00
0.00
0.00
0.00
3.00
2.00
1.70
1.80
2.40
2.20
2.30
growth rate -33.3% -15.0% 5.9% 33.3% -8.3% 4.6%
Cur.Liabilities 314.30
299.50
250.30
306.06
413.40
501.20
538.36
571.80
494.41
566.06
610.62
growth rate -4.7% -16.4% 22.3% 35.1% 21.2% 7.4% 6.2% -13.5% 14.5% 7.9%
Liabilities 410.90
336.20
279.50
345.97
447.50
531.90
578.64
954.11
880.67
955.62
999.97
growth rate -18.2% -16.9% 23.8% 29.4% 18.9% 8.8% 64.9% -7.7% 8.5% 4.6%
LT Debt 65.20
0.00
0.00
0.00
0.00
0.00
0.00
348.31
348.51
348.89
349.26
growth rate -100.0% 0.1% 0.1% 0.1%
Equity 456.40
572.20
670.00
681.54
754.60
910.60
950.21
763.10
945.17
1,191.00
1,354.28
growth rate 25.4% 17.1% 1.7% 10.7% 20.7% 4.4% -19.7% 23.9% 26.0% 13.7%
Common Shares 60.00
60.00
61.00
61.00
60.00
62.00
63.00
60.00
56.00
55.00
55.00
growth rate 0.0% 1.7% 0.0% -1.6% 3.3% 1.6% -4.8% -6.7% -1.8% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 67.90
33.80
31.00
35.28
31.00
29.49
32.78
49.73
42.60
44.72
48.40
growth rate -50.2% -8.3% 13.8% -12.1% -4.9% 11.2% 51.7% -14.3% 5.0% 8.2%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 81.30
255.10
87.40
20.19
113.40
221.20
169.04
279.07
259.20
383.08
268.64
growth rate 213.8% -65.7% -76.9% 461.6% 95.1% -23.6% 65.1% -7.1% 47.8% -29.9%
FCF per Share 0.22
3.69
0.93
-0.28
1.37
1.69
2.58
3.11
3.71
6.71
4.81
growth rate 1,577.3% -74.8% -100.0% 100.0% 23.4% 52.7% 20.5% 19.3% 80.9% -28.3%
Sale Purchase of Stock -4.53
-15.90
0.00
22.27
21.00
10.18
-119.28
growth rate 0.0% 0.0% -5.7% -51.5% -100.0%
FCF 13.00
221.00
56.00
-15.00
83.00
192.00
137.00
230.00
217.00
338.00
220.00
growth rate 1,600.0% -74.7% -100.0% 100.0% 131.3% -28.7% 67.9% -5.7% 55.8% -34.9%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 865.20
887.60
1,263.10
945.73
1,504.00
1,784.30
1,503.32
1,574.98
1,666.49
1,758.44
2,595.78
growth rate 2.6% 42.3% -25.1% 59.0% 18.6% -15.8% 4.8% 5.8% 5.5% 47.6%
Op.Income 99.50
107.50
92.10
22.88
55.40
102.80
211.15
281.54
319.85
343.59
385.85
growth rate 8.0% -14.3% -75.2% 142.1% 85.6% 105.4% 33.3% 13.6% 7.4% 12.3%
IBT 98.30
104.70
92.70
29.00
67.20
120.90
202.72
278.85
300.17
328.06
364.61
growth rate 6.5% -11.5% -68.7% 131.8% 79.9% 67.7% 37.6% 7.7% 9.3% 11.1%
Net Income 78.10
94.30
87.10
22.88
55.40
102.80
172.47
239.54
262.18
281.49
322.66
growth rate 20.7% -7.6% -73.7% 142.1% 85.6% 67.8% 38.9% 9.5% 7.4% 14.6%
EPS 1.30
1.57
1.44
0.37
0.92
1.65
2.73
3.97
4.65
5.13
5.89
growth rate 20.8% -8.3% -74.3% 148.7% 79.4% 65.5% 45.4% 17.1% 10.3% 14.8%
Gross Profit 376.00
379.80
358.70
333.81
397.10
1,336.10
600.15
666.00
705.15
731.13
777.56
growth rate 1.0% -5.6% -6.9% 19.0% 236.5% -55.1% 11.0% 5.9% 3.7% 6.4%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 94.40
97.94
101.79
101.95
106.09
growth rate 3.8% 3.9% 0.2% 4.1%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 751.62
771.75
837.62
922.83
994.82
growth rate 2.7% 8.5% 10.2% 7.8%
Acct.Payable 15.12
15.31
46.53
19.30
20.23
growth rate 1.2% 204.0% -58.5% 4.8%
Cur.Assets 1,148.65
1,305.54
1,330.18
1,440.53
1,467.11
growth rate 13.7% 1.9% 8.3% 1.9%
Total Assets 2,174.50
2,325.73
2,354.26
2,607.26
2,719.10
growth rate 7.0% 1.2% 10.8% 4.3%
Cash 289.22
426.22
395.85
417.64
370.21
growth rate 47.4% -7.1% 5.5% -11.4%
Inventory 2.30
growth rate
Cur.Liabilities 548.25
602.14
610.62
712.27
708.82
growth rate 9.8% 1.4% 16.7% -0.5%
Liabilities 935.75
991.24
999.97
1,185.07
1,190.22
growth rate 5.9% 0.9% 18.5% 0.4%
LT Debt 349.07
349.17
349.26
349.36
349.45
growth rate 0.0% 0.0% 0.0% 0.0%
Equity 1,238.75
1,334.48
1,354.28
1,422.19
1,495.92
growth rate 7.7% 1.5% 5.0% 5.2%
Common Shares 4.68
4.69
4.66
4.66
4.66
growth rate 0.1% -0.7% 0.0% 0.1%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 8.92
11.17
20.01
7.03
11.18
growth rate 25.3% 79.2% -64.9% 59.0%
Cash Dividends
growth rate
Cash From OA 39.20
128.11
60.86
94.63
22.74
growth rate 226.8% -52.5% 55.5% -76.0%
Sale Purchase of Stock
growth rate
FCF 30.29
116.94
40.85
87.60
11.55
growth rate 286.1% -65.1% 114.4% -86.8%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 641.61
655.02
679.03
674.85
695.14
growth rate 2.1% 3.7% -0.6% 3.0%
Op.Income 94.40
97.94
101.79
101.95
106.09
growth rate 3.8% 3.9% 0.2% 4.1%
IBT 79.63
96.05
100.19
100.34
104.67
growth rate 20.6% 4.3% 0.2% 4.3%
Net Income 71.87
84.53
88.16
88.30
91.86
growth rate 17.6% 4.3% 0.2% 4.0%
EPS
growth rate
Gross Profit 361.70
375.46
-307.89
200.26
204.48
growth rate 3.8% -100.0% 100.0% 2.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (76.21)

YOY Growth Grade:

C (50.21)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 23.39 25.90 18.75
EPS / Growth 33.4% 6.10 10.6%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 12.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 10.6% 11.5% 11.5%
Future PE 18.75 21.70 21.70
Future EPS 16.75 18.08 18.08
Value Price
MOS %
77.61
-50.9%
96.98
-38.6%
96.98
-38.6%
MOS Price 38.81 48.49 48.49
IRT 12.36 11.95 11.95

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.